Network pharmacology-based anti-pancreatic cancer potential of kaempferol and catechin of Trema orientalis L. through computational approach.
ADMET
HRMS
Hub gene
MFETO
Pancreatic cancer
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
03 Apr 2023
03 Apr 2023
Historique:
received:
05
11
2022
accepted:
10
03
2023
medline:
5
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
In pancreatic cancer, healthy cells in the pancreas begin to malfunction and proliferate out of control. According to our conventional knowledge, many plants contain several novel bioactive compounds, having pharmaceutical applications for the treatment of disease like pancreatic cancer. The methanolic fraction of fruit extract of Trema orientalis L. (MFETO) was analysed through HRMS. In this in silico study, pharmacokinetic and physicochemical properties of the identified flavonoids from MFETO were screened out by ADMET analysis. Kaempferol and catechin followed Lipinski rules and showed no toxicity in Protox II. Targets of these compounds were taken from SwissTarget prediction and TCMSP whilst targets for pancreatic cancer were taken from GeneCards and DisGeNET databases. The protein-protein interaction (PPI) network of common genes was generated through STRING and then exported to the Cytoscape to get top 5 hub genes (AKT1, SRC, EGFR, TNF, and CASP3). The interaction between compounds and hub genes was analysed using molecular docking, and high binding affinity between them can be visualised by Biovia discovery studio visualizer. Our study shows that, five hub genes related to pancreatic cancer play an important role in tumour growth induction, invasion and migration. Kaempferol effectively check cell migration by inhibiting ERK1/2, EGFR-related SRC, and AKT pathways by scavenging ROS whilst catechin inhibited TNFα-induced activation and cell cycle arrest at G1 and G2/M phases by induction of apoptosis of malignant cells. Kaempferol and catechin containing MFETO can be used for formulation of potent drugs for pancreatic cancer treatment in future.
Identifiants
pubmed: 37010624
doi: 10.1007/s12032-023-01996-w
pii: 10.1007/s12032-023-01996-w
doi:
Substances chimiques
Catechin
8R1V1STN48
Kaempferols
0
ErbB Receptors
EC 2.7.10.1
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement. JAMA. 2019;322(5):438–444. doi: https://doi.org/10.1001/jama.2019.10232
Jin C, Bai L. Pancreatic cancer – current situation and challenges. Gastroenterol Hepatol Lett. 2020;2(1):1–3. https://doi.org/10.18063/ghl.v2i1.243 .
doi: 10.18063/ghl.v2i1.243
Chang MC, Wong JM, Chang YT. Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol. 2014;20(9):2358–64. https://doi.org/10.3748/wjg.v20.i9.2358 .
doi: 10.3748/wjg.v20.i9.2358
pubmed: 24605033
pmcid: 3942839
Ohmoto A, Yachida S, Morizane C. Genomic features and clinical management of patients with hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci. 2019;20(3):561. https://doi.org/10.3390/ijms20030561 .
doi: 10.3390/ijms20030561
pubmed: 30699894
pmcid: 6387417
Yue Q, Gao G, Zou G, Yu H, Zheng X. Natural products as adjunctive treatment for pancreatic cancer: recent trends and advancements. Biomed Res Int. 2017;2017:8412508. https://doi.org/10.1155/2017/8412508 .
doi: 10.1155/2017/8412508
pubmed: 28232946
pmcid: 5292383
Stan SD, Singh SV, Brand RE. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2010;7(6):347–56. https://doi.org/10.1038/nrgastro.2010.61 .
doi: 10.1038/nrgastro.2010.61
pubmed: 20440279
pmcid: 2927967
Ying J-E, Zhu L-M, Liu B-X. Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol. 2012;18(8):736–45. https://doi.org/10.3748/wjg.v18.i8.736 .
doi: 10.3748/wjg.v18.i8.736
pubmed: 22371633
pmcid: 3286136
Akinleye A, Iragavarapu C, Furqan M, Cang S, Liu D. Novel agents for advanced pancreatic cancer. Oncotarget. 2015;6(37):39521–37. https://doi.org/10.18632/oncotarget.3999 .
doi: 10.18632/oncotarget.3999
pubmed: 26369833
pmcid: 4741843
Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao F. Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27(27):4298–321. https://doi.org/10.3748/wjg.v27.i27.4298 .
doi: 10.3748/wjg.v27.i27.4298
pubmed: 34366606
pmcid: 8316912
Schwarz RE, Donohue CA, Sadava D, Kane SE. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Lett. 2003;189(1):59–68. https://doi.org/10.1016/s0304-3835(02)00501-3 .
doi: 10.1016/s0304-3835(02)00501-3
pubmed: 12445678
Napiroon T, Tanruean K, Poolprasert P, Bacher M, Balslev H, Poopath M, Santimaleeworagun W. Cannabinoids from inflorescences fractions of Trema orientalis (L) Blume (Cannabaceae) against human pathogenic bacteria. PeerJ. 2021;9:e11446. https://doi.org/10.7717/peerj.11446 .
doi: 10.7717/peerj.11446
pubmed: 34035994
pmcid: 8126263
Adinortey MB, Galyuon IK, Asamoah NO. Trema orientalis Linn. Blume: A potential for prospecting for drugs for various uses. Pharmacogn Rev. 2013;7(13):67–72. https://doi.org/10.4103/0973-7847.112852 .
doi: 10.4103/0973-7847.112852
pubmed: 23922459
pmcid: 3731882
Parvez A, Azad M, Islam M, Munna MM, Shaheen S, Rahman MM. A phytochemical and pharmacological review on Trema orientalis: a potential medicinal plant. Pharmacologyonline. 2019;3:103–19.
Kumar P, Singh AK, Verma P, Tiwari KN, Mishra SK. Network pharmacology-based study on apigenin present in the methanolic fraction of leaves extract of Cestrum nocturnum L to uncover mechanism of action on hepatocellular carcinoma. Med Oncol. 2022;39(10):155. https://doi.org/10.1007/s12032-022-01759-z .
doi: 10.1007/s12032-022-01759-z
pubmed: 35852639
Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as anticancer agents. Nutrients. 2020;12(2):457. https://doi.org/10.3390/nu12020457 .
doi: 10.3390/nu12020457
pubmed: 32059369
pmcid: 7071196
Wang F, Wang L, Qu C, Chen L, Geng Y, Cheng C, Yu S, Wang D, Yang L, Meng Z, Chen Z. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling. BMC Cancer. 2021;21(1):396. https://doi.org/10.1186/s12885-021-08158-z .
doi: 10.1186/s12885-021-08158-z
pubmed: 33845796
pmcid: 8042867
Lee J, Kim JH. Kaempferol inhibits pancreatic cancer cell growth and migration through the blockade of EGFR-related pathway in vitro. PLoS One. 2016;11(5):e0155264. https://doi.org/10.1371/journal.pone.0155264 .
doi: 10.1371/journal.pone.0155264
pubmed: 27175782
pmcid: 4866780
Zhang Y, Chen AY, Li M, Chen C, Yao Q. Ginkgo biloba extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells. J Surg Res. 2008;148:17–23. https://doi.org/10.1016/j.jss.2008.02.036 .
doi: 10.1016/j.jss.2008.02.036
pubmed: 18570926
pmcid: 2924764
Fan FY, Sang LX, Jiang M. Catechins and their therapeutic benefits to inflammatory bowel disease. Molecules. 2017;22(3):484. https://doi.org/10.3390/molecules22030484 .
doi: 10.3390/molecules22030484
pubmed: 28335502
pmcid: 6155401
Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci. 2007;12:5039–51. https://doi.org/10.2741/2446 .
doi: 10.2741/2446
pubmed: 17569628
Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;10:1110–1. https://doi.org/10.1038/nbt1007-1110 .
doi: 10.1038/nbt1007-1110
Chandran U, Mehendale N, Patil S, Chaguturu R, Patwardhan B. Network pharmacology. Innovative approaches in drug discovery. 2017:127–64. doi: https://doi.org/10.1016/B978-0-12-801814-9.00005-2 .
Li S. Network pharmacology evaluation method guidance—draft. World J Tradit Chin Med. 2021;7:146–54.
doi: 10.4103/wjtcm.wjtcm_11_21
Zhang S, Lai X, Wang X, Liu G, Wang Z, Cao L, Zhang X, Xiao W, Li S. Deciphering the pharmacological mechanisms of Guizhi-Fuling capsule on primary dysmenorrhea through network pharmacology. Front Pharmacol. 2021;12:613104.
doi: 10.3389/fphar.2021.613104
pubmed: 33746752
pmcid: 7966503
Zhou W, Zhang H, Wang X, Kang J, Guo W, Zhou L, Liu H, Wang M, Jia R, Du X, Wang W, Zhang B, Li S. Network pharmacology to unveil the mechanism of Moluodan in the treatment of chronic atrophic gastritis. Phytomedicine. 2022;2022(95):153837.
doi: 10.1016/j.phymed.2021.153837
Zhou W, Lai X, Wang X, Yao X, Wang W, Li S. Network pharmacology to explore the anti-inflammatory mechanism of Xuebijing in the treatment of sepsis. Phytomedicine. 2021;85:153543.
doi: 10.1016/j.phymed.2021.153543
pubmed: 33799226
Stock NL. Introducing graduate students to high-resolution mass spectrometry (HRMS) using a hands-on approach. J Chem Educ. 2017;94(12):1978–82. https://doi.org/10.1021/acs.jchemed.7b00569 .
doi: 10.1021/acs.jchemed.7b00569
Rathahao-Paris E, Alves S, Junot C, et al. High resolution mass spectrometry for structural identification of metabolites in metabolomics. Metabolomics. 2016;12(10):1573–3890. https://doi.org/10.1007/s11306-015-0882-8 .
doi: 10.1007/s11306-015-0882-8
Tatsimo SJ, Tamokou Jde D, Havyarimana L, Csupor D, Forgo P, Hohmann J, Kuiate JR, Tane P. Antimicrobial and antioxidant activity of kaempferol rhamnoside derivatives from Bryophyllum pinnatum. BMC Res Notes. 2012;5:158. https://doi.org/10.1186/1756-0500-5-158 .
doi: 10.1186/1756-0500-5-158
pubmed: 22433844
pmcid: 3353177
Khanduja KL, Bhardwaj A. Stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids. Indian J Biochem Biophys. 2003;40(6):416–22.
pubmed: 22900369
Almatroodi SA, Almatroudi A, Khan AA, Alhumaydhi FA, Alsahli MA, Rahmani AH. Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant Catechin in green tea, and its role in the therapy of various types of cancer. Molecules. 2020;25(14):3146. https://doi.org/10.3390/molecules25143146 .
doi: 10.3390/molecules25143146
pubmed: 32660101
pmcid: 7397003
Kürbitz C, Heise D, Redmer T, Goumas F, Arlt A, Lemke J, Rimbach G, Kalthoff H, Trauzold A. Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci. 2011;102(4):728–34. https://doi.org/10.1111/j.1349-7006.2011.01870 .
doi: 10.1111/j.1349-7006.2011.01870
pubmed: 21241417
Bimonte S, Leongito M, Barbieri A, Del Vecchio V, Barbieri M, Albino V, Piccirillo M, Amore A, Di Giacomo R, Nasto A, Granata V, Petrillo A, Arra C, Izzo F. Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect Agent Cancer. 2015;10:22. https://doi.org/10.1186/s13027-015-0016-y .
doi: 10.1186/s13027-015-0016-y
pubmed: 26225138
pmcid: 4518601
Lu CH, Chen WT, Hsieh CH, Kuo YY, Chao CY. Thermal cycling-hyperthermia in combination with polyphenols, epigallocatechin gallate and chlorogenic acid, exerts synergistic anticancer effect against human pancreatic cancer PANC-1 cells. PLoS One. 2019;14(5):e0217676. https://doi.org/10.1371/journal.pone.0217676 .
doi: 10.1371/journal.pone.0217676
pubmed: 31150487
pmcid: 6544372
Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers (Basel). 2011;3(2):1513–26. https://doi.org/10.3390/cancers3021513 .
doi: 10.3390/cancers3021513
pubmed: 24212772
Lin XM, Hu L, Gu J, Wang RY, Li L, Tang J, Zhang BH, Yan XZ, Zhu YJ, Hu CL, Zhou WP, Li S, Liu JF, Gonzalez FJ, Wu MC, Wang HY, Chen L. Choline kinase α mediates interactions between the epidermal growth factor receptor and mechanistic target of rapamycin complex 2 in hepatocellular carcinoma cells to promote drug resistance and xenograft tumor progression. Gastroenterology. 2017;152(5):1187–202. https://doi.org/10.1053/j.gastro.2016.12.033 .
doi: 10.1053/j.gastro.2016.12.033
pubmed: 28065789
Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001;159(2):431–7. https://doi.org/10.1016/s0002-9440(10)61714-2 .
doi: 10.1016/s0002-9440(10)61714-2
pubmed: 11485901
pmcid: 1850562
Parsons CM, Muilenburg D, Bowles TL, Virudachalam S, Bold RJ. The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res. 2010;30(9):3279–89.
pubmed: 20944098
pmcid: 4557882
Alcalá S, Mayoral-Varo V, Ruiz-Cañas L, López-Gil JC, Heeschen C, Martín-Pérez J, Sainz B Jr. Targeting SRC kinase signaling in pancreatic cancer stem cells. Int J Mol Sci. 2020;21(20):7437. https://doi.org/10.3390/ijms21207437 .
doi: 10.3390/ijms21207437
pubmed: 33050159
pmcid: 7588004
Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of SRC signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J. 2019;286(18):3510–39. https://doi.org/10.1111/febs.15011 .
doi: 10.1111/febs.15011
pubmed: 31330086
pmcid: 6771888
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–71. https://doi.org/10.1038/nrc2628 .
doi: 10.1038/nrc2628
pubmed: 19343034
Wajant H. The role of TNF in cancer. Results Probl Cell Differ. 2009;49:1–15. https://doi.org/10.1007/400_2008_26 .
doi: 10.1007/400_2008_26
pubmed: 19137269
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. https://doi.org/10.1038/nature07205 .
doi: 10.1038/nature07205
pubmed: 18650914
Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79-84. https://doi.org/10.1007/s10875-012-9847-0 .
doi: 10.1007/s10875-012-9847-0
pubmed: 23225204
Zhao X, Fan W, Xu Z, Chen H, He Y, Yang G, Yang G, Hu H, Tang S, Wang P, Zhang Z, Xu P, Yu M. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7(49):81110–22. https://doi.org/10.18632/oncotarget.13212 .
doi: 10.18632/oncotarget.13212
pubmed: 27835602
pmcid: 5348380
Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J Gastrointest Surg. 2004;8(8):1072–8. https://doi.org/10.1016/j.gassur.2004.09.054 .
doi: 10.1016/j.gassur.2004.09.054
pubmed: 15585396
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O’Sullivan B, He Z, Peng Y, Tan AC, Zhou L, Shen J, Han G, Wang XJ, Thorburn J, Thorburn A, Jimeno A, Raben D, Bedford JS, Li CY. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17(7):860–6. https://doi.org/10.1038/nm.2385 .
doi: 10.1038/nm.2385
pubmed: 21725296
pmcid: 3132290
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–51. https://doi.org/10.1093/nar/gkaa970 .
doi: 10.1093/nar/gkaa970
pubmed: 33125081
Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2010;139(1):292–303. https://doi.org/10.1053/j.gastro.2010.03.034 .
doi: 10.1053/j.gastro.2010.03.034
pubmed: 20303350